At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
|Podcasts|January 7, 2022
Pharmacy Focus Episode 38: The Revolutionary Impact of Dupilumab on Skin Conditions
Author(s)Jill Murphy, Associate Editor
Dupilumab has been a breakthrough treatment for patients with atopic dermatitis, but future studies are needed to continue learning about its strength.
Advertisement
In this week’s episode, we will be discussing dupilumab and its impact on atopic dermatitis with Dr. Peter Lio. If you would like to nominate a pharmacist or pharmacy staff member as a Pharmacy Hero, email AAntrim@pharmacytimes.com!
Advertisement
Related to this article
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
2
Understanding Kratom: Pharmacology, Safety, and Regulation
3
Survodutide Shows Cardiovascular Safety in SYNCHRONIZE-CVOT
4
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
5